微生物附着量检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、检测类型、应用、最终用户、地区和竞争格局划分），2021-2031年

全球微生物附着量检测市场预计将从2025年的26.5亿美元成长到2031年的57.7亿美元，复合年增长率（CAGR）为13.85%。微生物附着量检测是指对产品、组件和包装上的活微生物数量进行量化的微生物分析，是製药和医疗保健行业灭菌验证和常规品管的关键前提。推动市场成长的主要因素包括严格的无菌保证监管要求、全球医疗设备产量不断增长以及对病人安全日益重视以预防医疗相关感染。根据欧洲医疗技术协会（MedTech Europe）的报告，欧洲医疗技术市场预计到2024年将达到约1,700亿欧元。如此大规模的生产规模催生了对严格微生物限度检测的持续需求，以确保产品在推出市场前符合安全标准。

然而，市场面临一个重大障碍，即缺乏能够进行这些复杂微生物检测并解读检测结果的合格专业人员。随着调查方法的不断发展和监管要求的日益复杂，缺乏训练有素的人员可能会造成营运瓶颈。因此，这种人才短缺限制了实验室有效处理日益增长的样本量的能力。

市场驱动因素

因污染导致的召回事件不断增加，是推动微生物附着量检测市场发展的主要因素。製造商为减少经济损失和声誉损害，监管机构对无菌缺陷的审查日益严格，迫使企业在整个生产週期中实施严格的微生物附着量评估，以便及早发现微生物污染。根据 Sedgwick 于 2025 年 2 月发布的《2025 年美国召回指数》，2024 年医疗设备召回事件增加了 8.6%。这一趋势凸显了全面微生物检测策略的迫切性。此外，对无菌保证的重视与医疗保健效果的改善密切相关。美国疾病管制与预防中心 (CDC) 报告称，2024 年急性照护医院中央静脉导管相关血流感染的发生率下降了 15%。

同时，生命科学研发领域不断增长的投资正在催生大量需要进行广泛微生物附着量测试的新疗法。随着製药公司投入资金开发复杂的生物製药，非临床和临床阶段需要进行微生物限度测试的样本数量呈现爆炸性成长。根据欧洲製药工业协会联合会（EFPIA）于2024年11月发布的《2024年製药业统计报告》，预计2024年欧洲製药业的研发投资将达到550亿欧元。如此庞大的投资推动了进入研发管线的产品数量持续成长，也使得严格的微生物分析以满足安全标准成为必然要求。

市场挑战

熟练专业人员的短缺是限制全球微生物附着量检测市场成长的一大阻碍因素。由于微生物附着量检测需要精确的微生物分析以确保无菌性和安全性，实验室高度依赖具备专业技术知识的人员来执行复杂的检测并准确解读数据。当检测机构面临合格人员短缺时，就会出现迫在眉睫的营运瓶颈，限制其处理来自製药和医疗设备製造商日益增长的样品量的能力。这种营运扩张的困难会导致检测积压和周转时间延长，从而延误灭菌验证，并最终导致医疗产品上市延迟。

因此，这些延误扰乱了供应链，延缓了製造商的收入实现，并间接抑制了对外包侦测服务的整体需求。近期产业调查结果凸显了人才短缺的严重性。据美国临床病理学会 (ASCP) 称，实验室人员流动率将持续上升至 2024 年，在接受调查的 17 个部门中，有 10 个部门报告称员工流动率较上次调查有所增加。经验丰富的人才持续减少，且缺乏足够的补充，这直接限制了市场的扩张能力，并使其难以达到业界严格的安全标准。

市场趋势

机器人技术和检查室自动化的整合正在从根本上重塑微生物附着量检测的工作流程，以高精度的机械系统取代劳动密集的手动操作。检查室正越来越多地采用自动化液体处理设备和机器人进样器来标准化样品製备和培养流程，从而显着提高检测通量和数据可重复性。这种操作方式的转变直接解决了高通量检测环境中一致性的重要性，因为人为干预是变异的常见来源，而这种转变降低了无菌检测不合格的风险。根据CRB（2024年10月）发布的《2024年生命科学展望报告》，31%的受访业者将数位化和自动化转型计划列为重点资本投资项目，凸显了该产业在品管基础设施现代化方面所做的努力。

同时，越来越多的製药企业将微生物附着量检测外包给受託研究机构(CRO)，以优化营运成本并利用外部技术诀窍。将常规微生物限度检测外包给外部实验室，使企业能够将内部资源重新分配到核心药物研发活动中，同时避免维护大规模内部检测设施所需的大量资本支出。随着监管合规性日益复杂，企业对外部合作伙伴的策略依赖预计将进一步增加。根据 CPHI 于 2024 年 9 月发布的《2024 年年度报告》，49% 的行业专家对未来 18 个月合约服务的成长持「非常乐观」的看法，这反映出整个行业对外包支援作用不断扩大的信心。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球微生物附着量检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（消耗品、设备）
  • 依检测类型（厌氧菌计数检测、霉菌或真菌计数检测、需气菌计数检测、孢子计数检测）
  • 依应用领域（原料检测、医疗设备检测、灭菌验证检测、进程内检测、设备清洁验证）
  • 按最终用户（製药/生物技术公司、医疗设备製造商、契约製造组织 (CMO) 及其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美微生物附着量检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲微生物附着量检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区微生物附着量检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲微生物附着量检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲微生物附着量检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球微生物附着量检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Charles River Laboratories
• Merck KGaA
• Thermo Fisher Scientific
• SGS SA
• Becton, Dickinson and Company
• bioMerieux SA
• Eurofins Scientific
• Nelson Laboratories
• WuXi AppTec
• Sartorius AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Bioburden Testing Market is projected to expand from USD 2.65 Billion in 2025 to USD 5.77 Billion by 2031, registering a CAGR of 13.85%. Defined as the microbiological analysis used to quantify viable microorganism populations on products, components, or packaging, bioburden testing is a vital prerequisite for sterilization validation and routine quality control within the pharmaceutical and healthcare sectors. Key drivers fueling market growth include strict regulatory mandates for sterility assurance, rising global medical device production, and an intensified focus on patient safety to prevent healthcare-associated infections. As reported by MedTech Europe, the European medical technology market was valued at approximately €170 billion in 2024. This massive manufacturing scale creates a sustained demand for rigorous microbial limit testing to guarantee that products satisfy safety standards prior to market entry.

However, the market faces a substantial obstacle in the form of a shortage of skilled professionals qualified to execute these complex microbiological assessments and interpret the resulting data. As testing methodologies advance and regulatory requirements become more intricate, the insufficiency of adequately trained personnel risks creating operational bottlenecks. Consequently, this workforce gap limits the capacity of testing facilities to effectively manage increasing sample volumes.

Market Driver

The increasing incidence of product recalls attributed to contamination is a major force propelling the bioburden testing market, as manufacturers aim to mitigate financial losses and reputational damage. With regulatory bodies intensifying their scrutiny of sterility failures, companies are compelled to adopt rigorous bioburden assessments throughout the production cycle to detect microbial contamination early. According to Sedgwick's '2025 US State of the Nation Recall Index' released in February 2025, medical device recall events rose by 8.6% in 2024. This trend highlights the critical urgency for comprehensive microbial detection strategies. Furthermore, this focus on sterility assurance correlates with improved health outcomes; the Centers for Disease Control and Prevention reported a 15% decline in central line-associated bloodstream infections in acute care hospitals in 2024.

Simultaneously, growing investments in life sciences research and development are generating a robust pipeline of new therapeutics that necessitate extensive bioburden testing. As pharmaceutical firms channel capital into developing complex biologics, the volume of samples requiring microbial limit testing during pre-clinical and clinical phases has surged. According to the 'The Pharmaceutical Industry in Figures 2024' report by the European Federation of Pharmaceutical Industries and Associations in November 2024, the industry invested an estimated €55,000 million in R&D across Europe in 2024. This substantial investment drives a continuous influx of products entering the pipeline, sustaining the demand for rigorous microbiological analysis to meet safety standards.

Market Challenge

A scarcity of skilled professionals serves as a significant constraint hampering the growth of the Global Bioburden Testing Market. Because bioburden testing requires precise microbiological analysis to ensure sterility and safety, laboratories rely heavily on personnel with specialized technical expertise to execute complex assays and accurately interpret data. When testing facilities confront a shortage of qualified staff, they face immediate operational bottlenecks that limit their capacity to process increasing sample volumes from pharmaceutical and medical device manufacturers. This inability to scale operations results in testing backlogs and extended turnaround times, which subsequently delay sterilization validation and the final release of medical products into the commerce stream.

Consequently, these delays disrupt supply chains and defer revenue realization for manufacturers, indirectly suppressing the overall demand for outsourced testing services. The severity of this workforce strain is highlighted by recent industry findings. According to the American Society for Clinical Pathology, in 2024, retirement rates within the laboratory sector continued to rise, with 10 out of 17 surveyed departments reporting increased personnel departures compared to previous assessments. This sustained loss of experienced talent without adequate replacement directly restricts the market's ability to expand and meet the rigorous safety standards required by the industry.

Market Trends

The integration of robotics and laboratory automation is fundamentally reshaping bioburden testing workflows by replacing labor-intensive manual tasks with high-precision mechanical systems. Laboratories are increasingly deploying automated liquid handling units and robotic plate loaders to standardize sample preparation and incubation processes, thereby significantly enhancing throughput and data reproducibility. This operational shift directly addresses the critical need for consistency in high-volume testing environments where human intervention often introduces variability, reducing the risk of sterility failures. According to CRB, October 2024, in the 'Horizons: Life Sciences Report 2024', 31% of surveyed industry respondents identified digitalization and automation conversion projects as their primary capital investment focus, underscoring the sector's commitment to modernizing quality control infrastructure.

Concurrently, a marked surge in outsourcing bioburden testing to Contract Research Organizations (CROs) is occurring as pharmaceutical manufacturers seek to optimize operational expenditures and leverage specialized external technical expertise. By delegating routine microbial limit testing to third-party laboratories, companies can redirect internal resources toward core drug development activities while avoiding the substantial capital costs associated with maintaining extensive in-house testing facilities. This strategic reliance on external partners is expected to intensify as the complexity of regulatory compliance grows. According to CPHI, September 2024, in the 'CPHI Annual Report 2024', 49% of industry professionals expressed a 'very positive' outlook regarding the growth of contract services over the subsequent 18 months, reflecting a strong industry-wide confidence in the expanding role of outsourced support.

Key Market Players

• Charles River Laboratories
• Merck KGaA
• Thermo Fisher Scientific
• SGS S.A.
• Becton, Dickinson and Company
• bioMerieux SA
• Eurofins Scientific
• Nelson Laboratories
• WuXi AppTec
• Sartorius AG

Report Scope

In this report, the Global Bioburden Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioburden Testing Market, By Product

• Consumables
• Instrument

Bioburden Testing Market, By Test Type

• Anerobic Count Testing
• Mold or Fungi Count Testing
• Aerobic Count Testing
• Spore Count Testing

Bioburden Testing Market, By Application

• Raw Material Testing
• Medical Devices Testing
• Sterilization Validation Testing
• In-process Testing
• Equipment Cleaning Validation

Bioburden Testing Market, By End User

• Pharmaceutical and Biotechnology Companies
• Medical Device Manufacturers
• Contract Manufacturing Organizations (CMO)
• others

Bioburden Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioburden Testing Market.

Available Customizations:

Global Bioburden Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bioburden Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Instrument)
  • 5.2.2. By Test Type (Anerobic Count Testing, Mold or Fungi Count Testing, Aerobic Count Testing, Spore Count Testing)
  • 5.2.3. By Application (Raw Material Testing, Medical Devices Testing, Sterilization Validation Testing, In-process Testing, Equipment Cleaning Validation)
  • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Medical Device Manufacturers, Contract Manufacturing Organizations (CMO), others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Bioburden Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Test Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bioburden Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Bioburden Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Bioburden Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Bioburden Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Test Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bioburden Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Bioburden Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Bioburden Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Bioburden Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Bioburden Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Bioburden Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Test Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bioburden Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Bioburden Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Bioburden Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Bioburden Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Bioburden Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Bioburden Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Test Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bioburden Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Bioburden Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Bioburden Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Bioburden Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Test Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bioburden Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Bioburden Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Bioburden Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bioburden Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Charles River Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Thermo Fisher Scientific
• 15.4. SGS S.A.
• 15.5. Becton, Dickinson and Company
• 15.6. bioMerieux SA
• 15.7. Eurofins Scientific
• 15.8. Nelson Laboratories
• 15.9. WuXi AppTec
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer